Today: 8 May 2026
IonQ Revenue Surge Puts Quantum Stocks Back in Focus, but QTUM ETF Shows Why Hype May Be Ahead
23 March 2026
2 mins read

IonQ Revenue Surge Puts Quantum Stocks Back in Focus, but QTUM ETF Shows Why Hype May Be Ahead

NEW YORK, March 23, 2026, 12:10 PM EDT

  • IonQ climbed roughly 4% by midday Monday, while QTUM advanced over 2%. Rigetti and D-Wave joined the move higher.
  • IonQ’s 2025 revenue landed at $130 million, dwarfing D-Wave’s $24.6 million and Rigetti’s $7.1 million.
  • QTUM’s assets have topped $3.5 billion, yet the fund’s exposure to four U.S. pure-play quantum stocks comes in at only 2.92%.

Quantum-computing stocks saw gains Monday—IonQ advanced roughly 4%, while Rigetti Computing and D-Wave Quantum also traded higher. By midday in New York, the Defiance Quantum ETF had added over 2%. Still, recent earnings reports suggest that significant revenue remains largely limited to a handful of players.

The split’s getting attention as investor flows chase the quantum theme ahead of mainstream takeup. Defiance reported QTUM crossed $3.5 billion in assets last month. Over in public markets, IonQ became the first quantum pure-play to hit $100 million in annual GAAP revenue—a milestone both D-Wave and Rigetti missed by a wide margin, booking $24.6 million and $7.1 million respectively for 2025.

IonQ stands out as the most straightforward growth play here. Revenue in 2025 soared 202% to $130 million, with commercial clients making up over 60% of that figure. Looking ahead, the company projects $225 million to $245 million in 2026 sales. “Strategic and financial inflection point”—that’s how CEO Niccolo de Masi described 2025. IonQ Investors

Still, IonQ’s story is all about the long runway. The company logged a net loss of $510.4 million for 2025, and as of Monday, its $18.3 billion valuation came in at over 140 times last year’s revenue. That’s before anyone knows if management’s $1.8 billion SkyWater agreement will actually give it the manufacturing muscle they’re aiming for.

D-Wave’s numbers are running hot. The company reported 2025 revenue up 179% to $24.6 million. By Feb. 25, first-quarter-to-date 2026 bookings were already past $32.8 million. CEO Alan Baratz put it plainly: D-Wave is heading into 2026 with “exceptional momentum.” D-Wave

Rigetti posted just $7.1 million in revenue for 2025. Still, Chief Executive Subodh Kulkarni pointed to growing interest from governments and research outfits—highlighting an $8.4 million order from India’s C-DAC for a 108-qubit system. For reference, a qubit is the basic unit of quantum information.

QTUM’s structure sheds some light on its wider appeal, outpacing the interest typically seen in single-stock bets. As of March 23, Nvidia and Alphabet each made up roughly 1.19% of the portfolio. IonQ, D-Wave, Rigetti, and Quantum Computing Inc—taken together—represented only 2.92% of assets.

QTUM isn’t strictly a quantum play—it’s more of a catch-all covering semis, software, and a spread of advanced computing names. Back in February, Defiance reported the ETF had topped $3.5 billion in assets. As of Feb. 28, its website showed a 49.26% one-year market-price return.

Government backing is propping up the sector, too. Last week, Britain pledged as much as 2 billion pounds for quantum technologies, with procurement programs aimed at pushing commercial-scale systems out of labs and into real-world domestic use.

Public markets keep betting on potential rather than profits. Steve Sosnick at Interactive Brokers summed it up: it’s about “the right price to pay for a piece of the future.” Defiance CIO Sylvia Jablonski points to the appeal—”science fiction has moved” into the business world. That disconnect is still the sector’s main play. Reuters

Stock Market Today

  • Omnicell (OMCL) Stock Analysis: 71% Rebound Sparks Revaluation Debate
    May 8, 2026, 7:58 AM EDT. Omnicell's shares have surged about 70.7% over the past year, closing recently at $43.33. The stock showed mixed performance with a 4% year-to-date decline but strong recent gains. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by nearly 20%, estimating an intrinsic value of $53.90 per share. Omnicell's latest twelve-month free cash flow stands at $95.6 million, with growth projected through 2030. Despite the rebound, long-term performance includes significant declines over three and five years, mirroring challenges in the healthcare technology and automation sector. Investors are encouraged to weigh these fundamentals carefully, as Omnicell scores 2 out of 6 in undervaluation checks per Simply Wall St, signaling mixed signals for value assessment.

Latest article

Tempus AI Just Priced a $400 Million Debt Deal. Here’s What Investors Need to Watch

Tempus AI Just Priced a $400 Million Debt Deal. Here’s What Investors Need to Watch

8 May 2026
Tempus AI priced a $400 million private sale of 0% convertible senior notes due 2032, upsized from $350 million, to repay $307.7 million in loans and fund operations. The deal follows first-quarter revenue of $348.1 million, up 36%, but a net loss widened to $125.9 million. Shares traded at $49.47 premarket, down $4.07. The notes convert at $69.26 per share, a 40% premium to the last close.
Iron Mountain Incorporated Stock Falls After Six-Day Rally as AI Data-Center Bet Faces New Test

Iron Mountain Incorporated Stock Falls After Six-Day Rally as AI Data-Center Bet Faces New Test

8 May 2026
Cohere agreed in April to acquire Germany’s Aleph Alpha, aiming to expand in regulated European markets as governments demand “sovereign AI.” Schwarz Group plans to invest $600 million in Cohere, which was valued at $6.8 billion last year. The merged company will be based in Germany and Canada, targeting sectors like finance and defence. The deal awaits shareholder and regulatory approval.
Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

Zoetis Stock Plunge: The Pet-Care Slowdown Wall Street Can’t Ignore

8 May 2026
Zoetis cut its 2026 revenue forecast to $9.68 billion-$9.96 billion and lowered adjusted EPS guidance after U.S. companion-animal product sales dropped 11% in the first quarter. Shares fell $23.86 to $87.31. First-quarter adjusted EPS came in at $1.53, missing analyst estimates of $1.61. CEO Kristin Peck cited weaker demand, fewer vet visits, and increased competition.
GE Aerospace Stock Gets Fresh Institutional Backing as New Filings Show Wall Street Split
Previous Story

GE Aerospace Stock Gets Fresh Institutional Backing as New Filings Show Wall Street Split

US Stock Market Today: Dow, S&P 500, Nasdaq Surge as Oil Tumbles on Iran Reprieve
Next Story

US Stock Market Today: Dow, S&P 500, Nasdaq Surge as Oil Tumbles on Iran Reprieve

Go toTop